Purpose <p>Patients with brain metastasis frequently exhibit baseline neurocognitive decline (NCD), which can be further exacerbated by CNS-directed interventions. Despite efforts to measure and preserve neurocognitive function (NCF), the practicality of traditional methods remains a concern. As a contemporary alternative, this study evaluates the feasibility and patient feedback of a novel digital neurocognitive assessment (NCA) tool.</p> Methods <p>Adult patients undergoing stereotactic radiosurgery (SRS), fractionated SRS (FSRS), or whole-brain radiotherapy (WBRT) from December 2021 to March 2024 were enrolled onto a prospective registry (NCT05504681), which formed the basis for this work. The multi-dimensional, multi-language digital NCA battery was administered at baseline and follow-up, and a feedback survey was collected to assess the tool’s usability and patient satisfaction.</p> Results <p>A “high risk” cohort of 74 patients with brain metastases and a “low risk” cohort of 14 patients with small benign extra-axial tumors were evaluated. The high risk cohort had higher rates of NCD compared to the low risk cohort (36.5% vs. 7.1%, <i>p</i> = 0.032); driven by patients treated with WBRT vs. SRS/FSRS (73.3% vs. 27.1%, <i>p</i> = 0.001). Notably, 50.0% completed the NCAs in their native language (non-English). Patient feedback indicated that 94% found the NCAs easy to understand, 96% found it easy to use, and 74% found it relevant to their care.</p> Conclusion <p>This multi-dimensional, multi-language tablet-based NCA tool demonstrated feasibility and patient acceptance in a diverse patient population as well as the ability to discriminate NCD among patients treated with SRS/FSRS vs. WBRT. This approach shows promise for broader implementation, warranting further validation to confirm its efficacy.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Integrating a novel tablet-based digital neurocognitive assessment tool in brain metastases patients

  • Eyub Y. Akdemir,
  • Selin Gurdikyan,
  • Thailin Companioni Reyes,
  • Yazmin Odia,
  • Miguel A. Ramirez Menendez,
  • Sreenija Yarlagadda,
  • Omer Gal,
  • Matthew D. Hall,
  • Robert H. Press,
  • D. Jay Wieczorek,
  • Yongsook C. Lee,
  • Ranjini Tolakanahalli,
  • Alonso N. Gutierrez,
  • Michael W. McDermott,
  • Manmeet S. Ahluwalia,
  • Minesh P. Mehta,
  • Rupesh Kotecha

摘要

Purpose

Patients with brain metastasis frequently exhibit baseline neurocognitive decline (NCD), which can be further exacerbated by CNS-directed interventions. Despite efforts to measure and preserve neurocognitive function (NCF), the practicality of traditional methods remains a concern. As a contemporary alternative, this study evaluates the feasibility and patient feedback of a novel digital neurocognitive assessment (NCA) tool.

Methods

Adult patients undergoing stereotactic radiosurgery (SRS), fractionated SRS (FSRS), or whole-brain radiotherapy (WBRT) from December 2021 to March 2024 were enrolled onto a prospective registry (NCT05504681), which formed the basis for this work. The multi-dimensional, multi-language digital NCA battery was administered at baseline and follow-up, and a feedback survey was collected to assess the tool’s usability and patient satisfaction.

Results

A “high risk” cohort of 74 patients with brain metastases and a “low risk” cohort of 14 patients with small benign extra-axial tumors were evaluated. The high risk cohort had higher rates of NCD compared to the low risk cohort (36.5% vs. 7.1%, p = 0.032); driven by patients treated with WBRT vs. SRS/FSRS (73.3% vs. 27.1%, p = 0.001). Notably, 50.0% completed the NCAs in their native language (non-English). Patient feedback indicated that 94% found the NCAs easy to understand, 96% found it easy to use, and 74% found it relevant to their care.

Conclusion

This multi-dimensional, multi-language tablet-based NCA tool demonstrated feasibility and patient acceptance in a diverse patient population as well as the ability to discriminate NCD among patients treated with SRS/FSRS vs. WBRT. This approach shows promise for broader implementation, warranting further validation to confirm its efficacy.